Literature DB >> 25630539

Genital Mycoplasma infections and their resistance phenotypes in an African setting.

L Kouegnigan Rerambiah1, J-C Ndong, S Medzegue, M Elisee-Ndam, J F Djoba Siawaya.   

Abstract

We investigated the antimicrobial susceptibilities of mycoplasmas in Gabonese men and women. A total of 1,332 men and women were included in the study. Sperm, urine, ureteral or vaginal swabs were collected from the subjects. Mycoplasmas identification and antimicrobial susceptibility to azithromycin, clarithromycin, erythromycin, josamycin, pristinamycin, doxycycline, tetracycline, ofloxacin and ciprofloxacin were tested using the Mycoplasma IST 2 kit. 794 subjects were positive for Mycoplasma. Respectively, 1.6 % and 82.24 % of subjects were singly infected with M. hominis and Ureaplasma urealyticum and 15.87 % had a mixed infection. M. hominis isolates were resistant to erythromycin and had an intermediate (I) to resistant (R) profile to azithromycin and clarithromycin. 84.6 % of M. hominis strains were sensitive (S) to josamycin and pristinamycin. 30.8 % and 92.3 % of M. hominis strains were sensitive to tetracycline and doxycycline, respectively. 76.9 and 84.6 % of M. hominis isolates were sensitive to ciprofloxacin and ofloxacin, respectively. The sensitivity rates of U. urealyticum strains were 45.23 %, 47.7 %, 63.84 %, 90.8 % and 92 % for azithromycin, erythromycin, clarithromycin, pristinamycin and josamycin, respectively. U. urealyticum strains showed 62.2 % and 79.7 % sensitivity to tetracycline and doxycycline, respectively. The resistance rates to azithromycin, clarithromycin and erythromycin for samples with mixed infection were 72.8 %, 84.7 % and 85.6 %, respectively. Josamycin and pristinamycin were 81.5 % effective on samples with mixed infection. The sensitivity rates of samples with mixed infection to tetracycline, doxycycline, ciprofloxacin and ofloxacin were 32 %, 69.6 %, 8.9 % and 18.5 %, respectively. Sub-Saharan Africa needs to use antibiotics rationally, as falling to do so would compromise the management of infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25630539     DOI: 10.1007/s10096-015-2326-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  10 in total

Review 1.  Antimicrobial resistance in developing countries. Part II: strategies for containment.

Authors:  Iruka N Okeke; Keith P Klugman; Zulfiqar A Bhutta; Adriano G Duse; Philip Jenkins; Thomas F O'Brien; Ariel Pablos-Mendez; Ramanan Laxminarayan
Journal:  Lancet Infect Dis       Date:  2005-09       Impact factor: 25.071

Review 2.  Antimicrobial resistance in developing countries. Part I: recent trends and current status.

Authors:  Iruka N Okeke; Ramanan Laxminarayan; Zulfiqar A Bhutta; Adriano G Duse; Philip Jenkins; Thomas F O'Brien; Ariel Pablos-Mendez; Keith P Klugman
Journal:  Lancet Infect Dis       Date:  2005-08       Impact factor: 25.071

3.  Increase in resistance of Mycoplasma hominis to tetracyclines.

Authors:  M C Cummings; W M McCormack
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

4.  Comparative in-vitro activity of levofloxacin, other fluoroquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis.

Authors:  U Ullmann; S Schubert; R Krausse
Journal:  J Antimicrob Chemother       Date:  1999-06       Impact factor: 5.790

Review 5.  Antibiotic susceptibilities of mycoplasmas and treatment of mycoplasmal infections.

Authors:  D Taylor-Robinson; C Bébéar
Journal:  J Antimicrob Chemother       Date:  1997-11       Impact factor: 5.790

6.  Antibiotic resistance of faecal Escherichia coli from healthy volunteers from eight developing countries.

Authors:  S Nys; I N Okeke; S Kariuki; G J Dinant; C Driessen; E E Stobberingh
Journal:  J Antimicrob Chemother       Date:  2004-10-07       Impact factor: 5.790

7.  Tetracycline resistance in Ureaplasma spp. and Mycoplasma hominis: prevalence in Bordeaux, France, from 1999 to 2002 and description of two tet(M)-positive isolates of M. hominis susceptible to tetracyclines.

Authors:  S Dégrange; H Renaudin; A Charron; C Bébéar; C M Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2007-11-19       Impact factor: 5.191

8.  In-vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 years.

Authors:  R Krausse; S Schubert
Journal:  Clin Microbiol Infect       Date:  2010-11       Impact factor: 8.067

9.  Prevalence and antimicrobial susceptibility of Ureaplasma urealyticum and Mycoplasma hominis in Chinese women with genital infectious diseases.

Authors:  Changtai Zhu; Jinming Liu; Yang Ling; Chunlei Dong; Tingting Wu; Xiaoyuan Yu; Yanfeng Hou; Liping Dong; Xiaowei Cheng
Journal:  Indian J Dermatol Venereol Leprol       Date:  2012 May-Jun       Impact factor: 2.545

10.  Antibiotic susceptibility profiles of Mycoplasma hominis and ureaplasma urealyticum isolated during a population-based study concerning women infertility in northeast romania.

Authors:  Mareş Mihai; Năstasă Valentin; Doroftei Bogdan; Chifiriuc Mariana Carmen; Bleotu Coralia; Socolov Demetra
Journal:  Braz J Microbiol       Date:  2011-01       Impact factor: 2.476

  10 in total
  3 in total

1.  Prevalence and antibiotic susceptibility of Ureaplasma urealyticum and Mycoplasma hominis in Xi'an, China.

Authors:  X-Y Zeng; N Xin; X-N Tong; J-Y Wang; Z-W Liu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-16       Impact factor: 3.267

2.  Mycoplasma Co-Infection Is Associated with Cervical Cancer Risk.

Authors:  Cameron Klein; Kandali Samwel; Crispin Kahesa; Julius Mwaiselage; John T West; Charles Wood; Peter C Angeletti
Journal:  Cancers (Basel)       Date:  2020-04-28       Impact factor: 6.639

Review 3.  How the Cervical Microbiota Contributes to Cervical Cancer Risk in Sub-Saharan Africa.

Authors:  Cameron Klein; Crispin Kahesa; Julius Mwaiselage; John T West; Charles Wood; Peter C Angeletti
Journal:  Front Cell Infect Microbiol       Date:  2020-02-12       Impact factor: 5.293

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.